Border to Coast Pensions Partnership Ltd Acquires 10,305 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

Border to Coast Pensions Partnership Ltd grew its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO) by 12.3% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 93,913 shares of the medical research company’s stock after buying an additional 10,305 shares during the quarter. Border to Coast Pensions Partnership Ltd’s holdings in Thermo Fisher Scientific were worth $48,824,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the stock. WINTON GROUP Ltd bought a new stake in shares of Thermo Fisher Scientific during the second quarter worth $332,000. Mercer Global Advisors Inc. ADV raised its holdings in Thermo Fisher Scientific by 37.4% during the 2nd quarter. Mercer Global Advisors Inc. ADV now owns 35,467 shares of the medical research company’s stock worth $19,522,000 after purchasing an additional 9,656 shares during the last quarter. Seven Eight Capital LP lifted its position in Thermo Fisher Scientific by 29.4% during the 2nd quarter. Seven Eight Capital LP now owns 2,586 shares of the medical research company’s stock valued at $1,430,000 after purchasing an additional 588 shares during the period. Paces Ferry Wealth Advisors LLC acquired a new stake in shares of Thermo Fisher Scientific during the 2nd quarter worth approximately $213,000. Finally, Foresight Group Ltd Liability Partnership acquired a new position in Thermo Fisher Scientific in the second quarter valued at approximately $259,000. Institutional investors and hedge funds own 89.23% of the company’s stock.

Insider Activity at Thermo Fisher Scientific

In related news, SVP Michael A. Boxer sold 2,000 shares of the business’s stock in a transaction on Friday, October 25th. The shares were sold at an average price of $560.16, for a total transaction of $1,120,320.00. Following the transaction, the senior vice president now directly owns 12,736 shares in the company, valued at approximately $7,134,197.76. The trade was a 13.57 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Marc N. Casper sold 10,000 shares of the company’s stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $530.26, for a total transaction of $5,302,600.00. Following the sale, the chief executive officer now directly owns 111,192 shares in the company, valued at $58,960,669.92. This trade represents a 8.25 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 47,150 shares of company stock valued at $25,954,465. 0.34% of the stock is owned by insiders.

Analysts Set New Price Targets

A number of analysts have commented on the stock. Barclays lowered their target price on shares of Thermo Fisher Scientific from $620.00 to $610.00 and set an “equal weight” rating for the company in a report on Wednesday, October 23rd. Morgan Stanley dropped their price objective on Thermo Fisher Scientific from $670.00 to $647.00 and set an “overweight” rating for the company in a report on Monday. Stifel Nicolaus decreased their target price on Thermo Fisher Scientific from $680.00 to $665.00 and set a “buy” rating for the company in a research report on Thursday, October 24th. Bank of America cut their price target on shares of Thermo Fisher Scientific from $675.00 to $660.00 and set a “buy” rating on the stock in a research report on Friday, December 13th. Finally, TD Cowen upped their target price on shares of Thermo Fisher Scientific from $656.00 to $686.00 in a research note on Tuesday, October 22nd. Four research analysts have rated the stock with a hold rating, eighteen have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, Thermo Fisher Scientific currently has a consensus rating of “Moderate Buy” and a consensus target price of $648.95.

Thermo Fisher Scientific Stock Up 1.8 %

TMO stock opened at $561.51 on Friday. The business has a 50-day moving average of $529.69 and a 200-day moving average of $568.01. Thermo Fisher Scientific Inc. has a fifty-two week low of $493.30 and a fifty-two week high of $627.88. The stock has a market capitalization of $214.78 billion, a P/E ratio of 35.20, a P/E/G ratio of 3.59 and a beta of 0.76. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.63 and a quick ratio of 1.26.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings results on Wednesday, October 23rd. The medical research company reported $5.28 earnings per share for the quarter, topping the consensus estimate of $5.25 by $0.03. Thermo Fisher Scientific had a net margin of 14.48% and a return on equity of 17.49%. The company had revenue of $10.60 billion during the quarter, compared to analysts’ expectations of $10.63 billion. During the same period last year, the business earned $5.69 EPS. The business’s quarterly revenue was up .2% on a year-over-year basis. On average, sell-side analysts anticipate that Thermo Fisher Scientific Inc. will post 21.68 earnings per share for the current fiscal year.

Thermo Fisher Scientific announced that its Board of Directors has initiated a stock buyback plan on Friday, November 15th that permits the company to repurchase $4.00 billion in shares. This repurchase authorization permits the medical research company to purchase up to 2% of its stock through open market purchases. Stock repurchase plans are often a sign that the company’s board believes its stock is undervalued.

Thermo Fisher Scientific Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, January 15th. Stockholders of record on Friday, December 13th were paid a dividend of $0.39 per share. The ex-dividend date of this dividend was Friday, December 13th. This represents a $1.56 dividend on an annualized basis and a dividend yield of 0.28%. Thermo Fisher Scientific’s dividend payout ratio is 9.78%.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.